Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study

To assess the in‐market use of Saxenda (liraglutide 3.0 mg) and Victoza (liraglutide 1.2 mg/1.8 mg) according to approved indications and posology.

[1]  Houde Zhou,et al.  Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials , 2022, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[2]  M. Nauck,et al.  Incretin hormones: Their role in health and disease , 2018, Diabetes, obesity & metabolism.

[3]  A. Mehta,et al.  Liraglutide for weight management: a critical review of the evidence , 2016, Obesity science & practice.

[4]  L. Aronne,et al.  Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial , 2016, International Journal of Obesity.

[5]  R. DeFronzo,et al.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.

[6]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[7]  L. Aronne,et al.  Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2014, International Journal of Obesity.

[8]  A. Barnett.  The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide , 2012, Diabetes, obesity & metabolism.

[9]  A. Garber,et al.  Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide , 2012, Diabetes, obesity & metabolism.

[10]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[11]  K. Niswender,et al.  Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay , 2010, Diabetes, obesity & metabolism.

[12]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[13]  L. Blonde,et al.  The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies , 2009, Diabetes, obesity & metabolism.

[14]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[15]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.